DNLIDenali Therapeutics Inc.
Price
+53%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, nothing alarming, the market undecided.
Denali Therapeutics Inc. ("Denali" or the “Company”) is a biopharmaceutical company, incorporated in Delaware, that discovers and develops therapeutics to defeat neurodegenerative diseases and lysosomal storage diseases. The Company is headquartered in South San Francisco, California. These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”).
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Denali Therapeutics Inc. (DNLI) reported revenue of $3.6M in Q2 2026 (quarter ended Jun 30, 2026). That came with a gross margin of 97% and net loss of $128M. For the full year FY2025, revenue was $0 and net income −$513M. Its largest product in Q2 2023 (quarter ended Jun 30, 2023) was ATV Abeta Program License at $294M, 100% of the disclosed total, well ahead of Option Services at 0.1%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights.Earnings release · press release
- Jul 28, 2026On July 27, 2026, Denali Therapeutics Inc. (the “Company”) completed the previously disclosed sale (the “Sale”) of its Rare Pediatric Disease Priority Review Voucher (the “PRV”) to a large pharmaceutical company.Acquisition or disposition completed · Form 8-K
- Jun 18, 2026On June 12, 2026, Denali Therapeutics Inc. (the “Company”) entered into an asset purchase agreement (the “PRV Transfer Agreement”), pursuant to which the Company agreed to sell its Rare Pediatric Disease Priority Review Voucher (“PRV”)Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2023 · $294.1MThe company’s own SEC segment disclosure.
- ATV Abeta Program License$293.9M100%
- Option Services$211.0K0%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.